Overview

Treating Insulin Resistance as a Strategy to Improve Outcome in Refractory Bipolar Disorder

Status:
Completed
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
In a previous study by Dr. Calkin, the principal investigator of this study, persons with bipolar disorder and either type II diabetes or insulin resistance were found to experience more severe symptoms of bipolar illness and a lower response to treatment, compared to persons with bipolar disorder who did not have type II diabetes or insulin resistance. To further explore these findings, the investigators have developed this study to see if treating insulin resistance (using metformin, a drug used to improve the body's use of insulin) may also help improve the symptoms of bipolar illness.
Phase:
Phase 3
Details
Lead Sponsor:
Cynthia Calkin
Collaborator:
Stanley Medical Research Institute
Treatments:
Insulin
Insulin, Globin Zinc
Metformin